Search Prime Grants

W81XWH2210245

Project Grant

Overview

Grant Description
Evaluation of the cardiac and metabolic effects of semaglutide in heart failure with preserved ejection fraction.
Awardee
Mayo Clinic
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Funding Agency
Medical Command (MEDCOM) [DoD - USA]
Place of Performance
Rochester, Minnesota 559050001 United States
Geographic Scope
Single Zip Code
Related Opportunity
0011740821
Mayo Clinic was awarded Cardiac Metabolic Effects of Semaglutide in HFpEF: A Randomized Trial Project Grant W81XWH2210245 worth $5,047,034 from Medical Command in July 2022 with work to be completed primarily in Rochester Minnesota United States. The grant has a duration of 4 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 7/22/22

Period of Performance
7/1/22
Start Date
6/30/26
End Date
82.0% Complete

Funding Split
$5.0M
Federal Obligation
$0.0
Non-Federal Obligation
$5.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W81XWH2210245

Transaction History

Modifications to W81XWH2210245

Additional Detail

Award ID FAIN
W81XWH2210245
SAI Number
None
Award ID URI
None
Awardee Classifications
Private Institution Of Higher Education
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
W81XWH W4PZ USA MED RSCH ACQUIS ACT
Funding Office
W91ZSQ W03J HQ CO USA MED DEV MAT CM
Awardee UEI
Y2K4F9RPRRG7
Awardee CAGE
5A021
Performance District
01
Senators
Amy Klobuchar
Tina Smith
Representative
Brad Finstad

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $5,047,034 100%
Modified: 7/22/22